87 related articles for article (PubMed ID: 25136033)
1. Response.
Moon BS; Cho YH; Jeong WJ; Choi KY
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25136033
[No Abstract] [Full Text] [Related]
2. Re: Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling.
Cristóbal I; Rincón R; Manso R; Rojo F; García-Foncillas J
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25136032
[No Abstract] [Full Text] [Related]
3. KRAS and cancer stem cells in APC-mutant colorectal cancer.
Fearon ER; Wicha MS
J Natl Cancer Inst; 2014 Feb; 106(2):djt444. PubMed ID: 24491303
[No Abstract] [Full Text] [Related]
4. Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling.
Moon BS; Jeong WJ; Park J; Kim TI; Min do S; Choi KY
J Natl Cancer Inst; 2014 Feb; 106(2):djt373. PubMed ID: 24491301
[TBL] [Abstract][Full Text] [Related]
5. [Stem cell theory of colorectal cancer and its connection with molecular-biological data].
Hagymási K; Molnár B; Sipos F; Galamb O; Tulassay Z
Orv Hetil; 2007 Apr; 148(17):779-85. PubMed ID: 17452307
[TBL] [Abstract][Full Text] [Related]
6. Arl4c is a key regulator of tubulogenesis and tumourigenesis as a target gene of Wnt-β-catenin and growth factor-Ras signalling.
Matsumoto S; Fujii S; Kikuchi A
J Biochem; 2017 Jan; 161(1):27-35. PubMed ID: 28053143
[TBL] [Abstract][Full Text] [Related]
7. Wnt/beta-catenin signaling in cancer stemness and malignant behavior.
Fodde R; Brabletz T
Curr Opin Cell Biol; 2007 Apr; 19(2):150-8. PubMed ID: 17306971
[TBL] [Abstract][Full Text] [Related]
8. Differential WNT activity in colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signaling.
Horst D; Chen J; Morikawa T; Ogino S; Kirchner T; Shivdasani RA
Cancer Res; 2012 Mar; 72(6):1547-56. PubMed ID: 22318865
[TBL] [Abstract][Full Text] [Related]
9. Wnt signalling pathway in the serrated neoplastic pathway of the colorectum: possible roles and epigenetic regulatory mechanisms.
Fu X; Li L; Peng Y
J Clin Pathol; 2012 Aug; 65(8):675-9. PubMed ID: 22412046
[TBL] [Abstract][Full Text] [Related]
10. Targeting Wnt signaling in colon cancer stem cells.
de Sousa EM; Vermeulen L; Richel D; Medema JP
Clin Cancer Res; 2011 Feb; 17(4):647-53. PubMed ID: 21159886
[TBL] [Abstract][Full Text] [Related]
11. RNA binding protein RBM3 increases β-catenin signaling to increase stem cell characteristics in colorectal cancer cells.
Venugopal A; Subramaniam D; Balmaceda J; Roy B; Dixon DA; Umar S; Weir SJ; Anant S
Mol Carcinog; 2016 Nov; 55(11):1503-1516. PubMed ID: 26331352
[TBL] [Abstract][Full Text] [Related]
12. CWP232228 targets liver cancer stem cells through Wnt/β-catenin signaling: a novel therapeutic approach for liver cancer treatment.
Kim JY; Lee HY; Park KK; Choi YK; Nam JS; Hong IS
Oncotarget; 2016 Apr; 7(15):20395-409. PubMed ID: 26967248
[TBL] [Abstract][Full Text] [Related]
13. BCL9/9L-β-catenin Signaling is Associated With Poor Outcome in Colorectal Cancer.
Moor AE; Anderle P; Cantù C; Rodriguez P; Wiedemann N; Baruthio F; Deka J; André S; Valenta T; Moor MB; Győrffy B; Barras D; Delorenzi M; Basler K; Aguet M
EBioMedicine; 2015 Dec; 2(12):1932-43. PubMed ID: 26844272
[TBL] [Abstract][Full Text] [Related]
14. [Expression of Wnt5a, APC, β-catenin and their clinical significance in human colorectal adenocarcinoma].
Cao YC; Yang F; Liu XH; Xin X; Wang CC; Geng M
Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):674-8. PubMed ID: 23159080
[TBL] [Abstract][Full Text] [Related]
15. Biology of colorectal cancer.
Saif MW; Chu E
Cancer J; 2010; 16(3):196-201. PubMed ID: 20526096
[TBL] [Abstract][Full Text] [Related]
16. Setting future standards for KRAS testing in colorectal cancer.
van Krieken H; Tol J
Pharmacogenomics; 2009 Jan; 10(1):1-3. PubMed ID: 19102707
[No Abstract] [Full Text] [Related]
17. A gene marker panel covering the Wnt and the Ras-Raf-MEK-MAPK signalling pathways allows to detect gene mutations in 80% of early (UICC I) colon cancer stages in humans.
Scholtka B; Schneider M; Melcher R; Katzenberger T; Friedrich D; Berghof-Jäger K; Scheppach W; Steinberg P
Cancer Epidemiol; 2009 Aug; 33(2):123-9. PubMed ID: 19679059
[TBL] [Abstract][Full Text] [Related]
18. KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.
de Reyniès A; Boige V; Milano G; Faivre J; Laurent-Puig P
J Clin Oncol; 2008 May; 26(13):2228-30; author reply 2230-1. PubMed ID: 18445856
[No Abstract] [Full Text] [Related]
19. Novel multiple, monoallelic KRAS mutations at codon 12 and 13.
Keller G; Geist B; Slotta-Huspenina J; Langer R; Nagl F; Fend F; Höfler H; Perren A
Int J Cancer; 2009 Dec; 125(11):2744-5. PubMed ID: 19521964
[No Abstract] [Full Text] [Related]
20. Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2.
Mologni L; Dekhil H; Ceccon M; Purgante S; Lan C; Cleris L; Magistroni V; Formelli F; Gambacorti-Passerini CB
Cancer Res; 2010 Sep; 70(18):7253-63. PubMed ID: 20823162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
